In aged mice, hepatocyte-specific deletion of p53 raised inflammation and immune infiltration, an effect absent in young mice. Without p53, hepatocytes accumulated DNA replication stress and DNA damage, lost expression of metabolic genes, and became more vulnerable to metabolic-stress liver injury. Pharmacologically activating p53 with the MDM2 inhibitor HDM201 reversed age-related suppression of metabolic genes, lowered inflammatory signatures, and delayed the onset of frailty. The evidence comes entirely from mice, not humans. This challenges the long-standing antagonistic pleiotropy view that p53 helps early in life but drives senescence and inflammation later. Loss-of-function data in aged animals are what the field has lacked, and they point the other way: p53 activity rises with age as a compensatory defense, not a driver of decline. The therapeutic angle is intriguing but carries a large caveat, since chronic p53 activation risks toxicity, and MDM2 inhibitors cause hematologic side effects in cancer trials. Liver-specific findings may also not generalize to other tissues, and the frailty benefit needs lifespan data and sex-specific replication. This is a preprint that has not undergone peer review, so conclusions may change. For readers, nothing here is actionable yet; it is a mechanistic reframing, important for geroscience but far from clinical translation.
Activating p53 with HDM201 Delays Frailty and Calms Inflammation in Aged Mice
Primary reference: bioRxiv preprint · View source ↗
⚠️ This is a preprint — it has not yet been peer-reviewed. Results should be interpreted with caution and may change following peer review.
Informational, non-clinical synthesis informed by published research. Not a clinical guideline or medical advice. May contain errors or editorial interpretation. Consult the original source and your physician.